Question | Discussion | References | CME Credit

Case 2: References

  1. Perelson AS, Neumann AU, Markowitz M, Leonard JM, Ho DD. HIV-1 dynamics in vivo: virion clearance rate, infected cell life-span, and viral generation time. Science. 1996;271:1582-6.
    [The following link will open in a new window. PubMed Abstract]
  2. O'Neil PK, Sun G, Yu H, Ron Y, Dougherty JP, Preston BD. Mutational analysis of HIV-1 long terminal repeats to explore the relative contribution of reverse transcriptase and RNA polymerase II to viral mutagenesis. J Biol Chem. 2002;277:38053-61.
    [The following link will open in a new window. PubMed Abstract]
  3. Hanna GJ, D'Aquila RT. Clinical use of genotypic and phenotypic drug resistance testing to monitor antiretroviral chemotherapy. Clin Infect Dis. 2001;32:774-82.
    [The following link will open in a new window. PubMed Abstract]
  4. Hirsch MS, Günthard HF, Schapiro JM, et al. Antiretroviral drug resistance testing in adult HIV-1 infection: 2008 recommendations of an International AIDS Society-USA panel. Clin Infect Dis. 2008;47:266-85.
    [The following link will open in a new window. PubMed Abstract]
  5. Johnson VA, Brun-Vezinet F, Clotet B, et al. Update of the Drug Resistance Mutations in HIV-1: Spring 2008. Top HIV Med. 2008;16:62-8.
    [The following link will open in a new window. PubMed Abstract]
  6. Larder BA, Kemp SD, Harrigan PR. Potential mechanism for sustained antiretroviral efficacy of AZT-3TC combination therapy. Science. 1995; 269:696-9.
    [The following link will open in a new window. PubMed Abstract]
  7. Durant J, Clevenbergh P, Halfon P, Delgiudice P, Porsin S, Simonet P, Montagne N, Boucher CA, Schapiro JM, Dellamonica P. Drug-resistance genotyping in HIV-1 therapy: the VIRADAPT randomised controlled trial. Lancet. 1999;353:2195-9.
    [The following link will open in a new window. PubMed Abstract]
  8. Baxter JD, Mayers DL, Wentworth DN, et al. A randomized study of antiretroviral management based on plasma genotypic antiretroviral resistance testing in patients failing therapy. CPCRA 046 Study Team for the Terry Beirn Community Programs for Clinical Research on AIDS. AIDS. 2000;14:F83-93.
    [The following link will open in a new window. PubMed Abstract]
  9. Tural C, Ruiz L, Holtzer C, et al. Clinical utility of HIV-1 genotyping and expert advice: the Havana trial. AIDS. 2002;16:209-18.
    [The following link will open in a new window. PubMed Abstract]
  10. Cingolani A, Antinori A, Rizzo MG, et al. Usefulness of monitoring HIV drug resistance and adherence in individuals failing highly active antiretroviral therapy: a randomized study (ARGENTA). AIDS. 2002;16:369-79.
    [The following link will open in a new window. PubMed Abstract]
  11. Meynard JL, Vray M, Morand-Joubert L, et al; the Narval Trial Group. Phenotypic or genotypic resistance testing for choosing antiretroviral therapy after treatment failure: a randomized trial. AIDS. 2002;16:727-36.
    [The following link will open in a new window. PubMed Abstract]
  12. Cohen CJ, Hunt S, Sension M, Farthing C, et al; VIRA3001 Study Team. A randomized trial assessing the impact of phenotypic resistance testing on antiretroviral therapy. AIDS. 2002;16:579-88.
    [The following link will open in a new window. PubMed Abstract]
  13. Haubrich RH, Kemper CA, Hellmann NS, et al. A randomized, prospective study of phenotype susceptibility testing versus standard of care to manage antiretroviral therapy: CCTG 575. AIDS. 2005;19:295-302.
    [The following link will open in a new window. PubMed Abstract]
  14. Deeks SG, Hellmann NS, Grant RM, et al. Novel four-drug salvage treatment regimens after failure of a human immunodeficiency virus type 1 protease inhibitor-containing regimen: antiviral activity and correlation of baseline phenotypic drug susceptibility with virologic outcome. J Infect Dis. 1999;179:1375-81.
    [The following link will open in a new window. PubMed Abstract]
  15. Walter H, Schmidt B, Rascu A, et al. Phenotypic HIV-1 resistance correlates with treatment outcome of nelfinavir salvage therapy. Antivir Ther. 2000;5:249-56.
    [The following link will open in a new window. PubMed Abstract]
  16. Finzi D, Blankson J, Sliciano JD, et al. Latent infection of CD4+ T cells provides a mechanism for lifelong persistence of HIV-1, even in patients on effective combination therapy. Nat Med. 1999;5:512-7.
    [The following link will open in a new window. PubMed Abstract]
  17. Deeks SG, Wrin T, Liegler T et al. Virologic and immunologic consequences of discontinuing combination antiretroviral-drug therapy in HIV-infected patients with detectable viremia. N Engl J Med. 2001;344:472-80.
    [The following link will open in a new window. PubMed Abstract]

[Back to Case 2 Question | Back to Discussion]

CME Credit | Back to Top